Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caroscio, J. T.
Right arrow Articles by Yahr, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caroscio, J. T.
Right arrow Articles by Yahr, M. D.
NEUROLOGY 1986;36:141
© 1986 American Academy of Neurology

A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis

James T. Caroscio, MD, Jeffrey A. Cohen, MD, Janet Zawodniak, RPT, Valerie Takai, OTR, Arnold Shapiro, MA, CCC, Steve Blaustein, MS, CCC, Michael N. Mulvihill, DrPH, Spiro P. Loucas, PhD, Mark Gudesblatt, MD, David Rube, BS and Melvin D. Yahr, MD

Departments of Neurology, Physical Medicine, Communication Disorders, and Community Medicine of the Mount Sinai School of Medicine, and the Pharmacy of The Mount Sinai Hospital, New York, NY.

A double-blind, placebo-controlled trial of single doses of thyrotropin releasing hormone (TRH) was performed on 12 patients with amyotrophic lateral sclerosis. Each patient was given subcutaneous injections of TRH 150 mg or placebo, and IV infusions of TRH 500 mg or placebo at 72-to 96-hour intervals. Eight motor and functional ratings were scored at regular intervals after each injection. Side effects were seen in all patients and were obvious to patients and examiners, making true blinding impossible. Nevertheless, statistically significant improvement was seen only in dynametric strength 1 hour after subcutaneous injection (p <0.05). Significant improvement occurred, in one patient only, on subjective speech testing during IV infusion of TRH. In none of six other ratings was there a significant difference between TRH and placebo. Subjective improvement was noted by 11 of 12 patients.

Address correspondence and reprint requests to Dr. Caroscio, Department of Neurology, The Mount Sinai Hospital, One Gustave L. Levy Place, New York, NY 10029.

Supported in part by NIH Grant #RR0071 from the Division of Research Resources, General Clinical Center Branch, and by The National ALS Foundation, Inc.

Accepted for publication May 8, 1985.




This article has been cited by other articles:


Home page
 NeurologyHome page
C. L. Howe, R. A. Bergstrom, B. F. Horazdovsky, E.J. Sorenson, A.J. Windbank, J.N. Mandrekar, W.R. Bamlet, S.H. Appel, C. Armon, P.E. Barkhaus, et al.
SUBCUTANEOUS IGF-1 IS NOT BENEFICIAL IN 2-YEAR ALS TRIAL
Neurology, October 13, 2009; 73(15): 1247 - 1248.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
J. M. Hoffman, J. C. Mazziotta, T. C. Hawk, and R. Sumida
Cerebral Glucose Utilization in Motor Neuron Disease
Arch Neurol, August 1, 1992; 49(8): 849 - 854.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
S. C. Miller and J. E. Warnick
Protirelin (Thyrotropin-Releasing Hormone) in Amyotrophic Lateral Sclerosis: The Role of Androgens
Arch Neurol, March 1, 1989; 46(3): 330 - 335.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
H. Mitsumoto, M. R. Hanson, and D. A. Chad
Amyotrophic Lateral Sclerosis: Recent Advances in Pathogenesis and Therapeutic Trials
Arch Neurol, February 1, 1988; 45(2): 189 - 202.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by AAN Enterprises, Inc.